Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Expression of a Novel Chimeric Inhibitory Receptor Attenuates CD19 CAR T Cells: A Promising Strategy for Toxicity Mitigation

Dustin A Cobb, Lixia Liu, Philip Mollica, III, Barbara Dziegielewska, Daniel W. Lee

Blood (2023) 142 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2023-186464

Published: 2023

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Blood (2021) 138 (14): 1237–1248.

https://doi.org/10.1182/blood.2020009064

Published: 2021

Includes: Supplemental data

Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-137233

Published: 2020

Journal Articles

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-135929

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

Anandani Nellan, Cynthia M. Lester McCully, Rafael Cruz Garcia, Nalini Jayaprakash, Brigitte C. Widemann, Daniel W. Lee, Katherine E. Warren

Blood (2018) 132 (6): 662–666.

https://doi.org/10.1182/blood-2018-05-846428

Published: 2018

Journal Articles

IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells

Melissa Mavers, MD, Federico Simonetta, MD PhD, Alexander W. Lee, Toshihito Hirai, MD PhD, Kristina Maas-Bauer, MD, Jeanette Baker, PhD, Maite Alvarez, PhD, Mustafa Turkoz, PhD, Everett H. Meyer, MD PhD, Robert S. Negrin, MD

Blood (2017) 130 (Supplement 1): 3199.

https://doi.org/10.1182/blood.V130.Suppl_1.3199.3199

Published: 2017

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Haneen Shalabi, DO, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD, Terry J Fry, MD

Blood (2016) 128 (22): 650.

https://doi.org/10.1182/blood.V128.22.650.650

Published: 2016

Journal Articles

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Haneen Shalabi, DO, Pamela L Wolters, PhD, Staci Martin, PhD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Daniel W. Lee, III, MD, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 1625.

https://doi.org/10.1182/blood.V128.22.1625.1625

Published: 2016

Journal Articles

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terry J. Fry, MD, Maryalice Stetler-Stevenson, MD PhD, Nirali N Shah, MD, Constance M. Yuan, MD PhD, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 1324.

https://doi.org/10.1182/blood.V126.23.1324.1324

Published: 2015

Journal Articles

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Yinmeng Yang, BS, Tasha Lin, MD, Elad Jacoby, MD, Haiying Qin, MS, Elizabeth Grier Gardner, MD, Christopher Daniel Chien, PhD, Daniel W. Lee, III, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 100.

https://doi.org/10.1182/blood.V126.23.100.100

Published: 2015

Journal Articles

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

David F. Stroncek, MD, Daniel W. Lee, III, MD, Jiaqiang Ren, MD PhD, Marianna Sabatino, MD, Hanh Khuu, MD, Melinda S. Merchant, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 383.

https://doi.org/10.1182/blood.V126.23.383.383

Published: 2015

Journal Articles

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Terry J. Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 684.

https://doi.org/10.1182/blood.V126.23.684.684

Published: 2015

Journal Articles

Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis

Stanley C. W. Lee, Sarah Miller, Craig Hyland, Maria Kauppi, Marion Lebois, Ladina Di Rago, Donald Metcalf, Sarah A. Kinkel, Emma C. Josefsson, Marnie E. Blewitt, Ian J. Majewski, Warren S. Alexander

Blood (2015) 126 (2): 167–175.

https://doi.org/10.1182/blood-2014-12-615898

Published: 2015

Includes: Supplemental data

Journal Articles

MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development

Bilal N. Sheikh, Stanley C. W. Lee, Farrah El-Saafin, Hannah K. Vanyai, Yifang Hu, Swee Heng Milon Pang, Stephanie Grabow, Andreas Strasser, Stephen L. Nutt, Warren S. Alexander, Gordon K. Smyth, Anne K. Voss, Tim Thomas

Blood (2015) 125 (12): 1910–1921.

https://doi.org/10.1182/blood-2014-08-594655

Published: 2015

Includes: Supplemental data

NARROW

Expression of a Novel Chimeric Inhibitory Receptor Attenuates CD19 CAR T Cells: A Promising Strategy for Toxicity Mitigation

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Infectious Complications Associated with CAR T-Cell Therapy

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis

MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only